Who is sponsoring NCT00532545?

NCT00532545 is sponsored by Eli Lilly and Company.

What condition does NCT00532545 study?

NCT00532545 studies Osteoporosis, Post-Menopausal.

What is the status of NCT00532545?

NCT00532545 is currently COMPLETED.

Last reviewed 2007-09-18 · How we verify

Bone Marker Changes In One Month Treatment With TERIPARATIDE (LY333334) Injections (rDNA Origin) in Men and Postmenopausal Women With Severe Osteoporosis

NCT00532545 Phase 4 COMPLETED

To test the hypothesis that Teriparatide injections given 20 micrograms/daily subcutaneously, for one month, are able to produce reliable changes in the bone marker in a severe osteoporotic population

Details

Lead sponsor	Eli Lilly and Company
Phase	Phase 4
Status	COMPLETED
Enrolment	45
Start date	2003-04
Completion	2004-04

Conditions

Osteoporosis, Post-Menopausal

Interventions

Teriparatide

Primary outcomes

To test the hypothesis that Teriparatide injections given 20 micrograms/daily subcutaneously, for one month, is able to produce reliable changes in the bone marker in a severe osteoporotic population in Puerto Rico.

Countries

Puerto Rico